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Feline leukaemia virus (FeLV) is a γ-retrovirus that was 
first described in 1964.1 It occurs worldwide in domesti-
cated cats and some related species.2,3 There are more 
studies published on antiviral treatment against FeLV 
infection than against any other virus infection in veteri-
nary medicine, but, to date, no treatment described has 
resulted in cure or complete virus elimination.4
Human interferon-α2a (huIFN-α2a) is commonly 
administered to cats, especially in countries such as the 
USA, where feline IFN (feIFN) is not available. In feline 
cell culture, replication of FeLV is inhibited by huIFN-
α2a, and its efficacy is 10 times greater than that of 
feIFN.5 In cats infected experimentally with FeLV, ‘low-
dose’ huIFN-α2a prolonged the survival time and 
delayed development of FeLV-associated diseases when 
compared with non-treated animals,6 and survival time 
was longer than in cats treated with bovine (boIFN-β).7
The compound 3’-azido-2’,3’-dideoxythymidine 
(zidovudine, AZT) has been used as an antiviral drug for 
patients infected with human immunodeficiency virus 
(HIV),8 as well as for cats infected with FeLV. It also 
inhibits FeLV replication in vitro.9 In experimentally-
infected cats, development of FeLV-associated lympho-
mas was delayed in AZT-treated cats compared with 
non-treated cats.10 Cats infected naturally with FeLV and 
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Abstract
Feline leukaemia virus (FeLV) infection is still one of the leading causes of infection-related deaths in domestic cats. 
Treatment with various drugs has been attempted, but none has resulted in cure or complete virus elimination. 
Human interferon-α2a (huIFN-α2a) and 3′-azido-2′,3′-dideoxythymidine (AZT) have been proven to decrease 
antigenaemia in cats infected experimentally with FeLV. The purpose of this study was to assess the efficacy 
of huIFN-α2a, AZT and a combination of both drugs in cats infected naturally with FeLV in a placebo-controlled 
double-blinded trial. Fourty-four FeLV-infected cats in which free FeLV p27 antigen was detected in serum by 
enzyme-linked immunosorbent assay were included in the study. Cats were assigned to one of four treatment 
groups that received either high dose huIFN-α2a (105 IU/kg q24h; 12 cats), AZT (5 mg/kg q12h; 10 cats, both 
of these treatments (12 cats) or placebo (10 cats). All cats were treated for 6 weeks. Clinical variables, including 
stomatitis, and laboratory parameters, such as CD4+ and CD8+ counts and serum FeLV p 27 antigen concentration, 
were recorded throughout the treatment period. No significant difference among the groups was observed during 
the treatment period for any of the parameters. Aside from anaemia in one cat treated with AZT, no adverse effects 
were observed. It was not possible to demonstrate efficacy of huIFN-α2a or AZT alone or together in cats infected 
naturally with FeLV when given according to this regimen for 6 weeks; however, no notable side effects were 
detected.
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treated with AZT for 3 weeks had significant improve-
ment in their stomatitis.11
The combination of ‘high-dose’ huIFN-α and AZT 
seemed to be particularly promising. In a placebo-
controlled study, prophylactic treatment of cats 
infected experimentally with FeLV using a combina-
tion of AZT and huIFN-α2a prevented development 
of persistent viraemia.12 In addition, initiation of 
treatment with AZT and huIFN-α2a in cats infected 
experimentally with FeLV with high levels of persis-
tent antigenaemia, but prior to development of clini-
cal signs, resulted in a significant decrease in FeLV 
p27 antigen levels 2 weeks after initiation of therapy.13 
Therefore, the combination of AZT and huIFN-α2a 
was clearly effective under experimental conditions. 
Thus, the aim of this study was to evaluate the effi-
cacy of huIFN-α2a and AZT in cats infected naturally 
with FeLV. Specifically, clinical signs, changes in CD4+ 
and CD8+ counts, and serum FeLV p 27 antigen con-
centrations were assessed. The primary hypothesis of 
the study was that FeLV antigen concentration would 
decrease by at least 60% within 6 weeks of treatment 
in naturally-infected cats. The secondary study 
hypothesis was that stomatitis would clinically 
improve within the same time period.
Materials and methods
Study design
The prospective study was designed as a placebo-con-
trolled double-blinded clinical trial. It fulfilled the gen-
eral German guidelines for prospective studies with 
appropriate owner consent. Forty-four cats were 
included and assigned randomly to one of four treat-
ment groups. All cats stayed in the hospital during the 
6-week treatment period. Cats in each group received 
one capsule PO q12h containing either AZT (5 mg/kg) 
(Retrovir; Glaxo Wellcome) or placebo (mannitol and 
aerosil), as well as one syringe SC q24h containing either 
huIFN-α2a (105 IU/kg) (Roferin-A Roche; Hoffmann-La 
Roche) or placebo (sterile physiologic saline, 0.9%). 
Twelve cats received only huIFN-α2a, 10 cats received 
only AZT, 12 cats received both AZT and huIFN-α2a, 
and 10 cats received only placebo.
Feline patients
A total of 44 client-owned feline patients of the Clinic of 
Small Animal Medicine, LMU University of Munich, 
Germany, were included. Ten (23%) were female intact, 
11 (25%) were female spayed, one (2%) was male intact 
and 22 (50%) were male neutered. The age of 38 of the 
44 cats was known; these cats were between 1 and 10 
years of age (median 4.3 years). Cats were eligible to 
enter the study if they had two positive FeLV test results 
[feline immunodeficiency virus (FIV)/FeLV combina-
tion test kit; Feline Leukemia Virus Antigen/Feline 
Immunodeficiency Virus Antibody Test Kit; Idexx]. 
Cats that tested positive for FIV, cats in moribund con-
dition and cats showing aggressive behaviour were 
excluded.
Variables investigated
Variables investigated throughout the study to detect 
efficacy and adverse effects included clinical signs, labo-
ratory parameters, CD4+ and CD8+ counts and the CD4/
CD8 ratio, and a quantitative measurement of FeLV p27 
antigen. For the parameter stomatitis, a numerical scor-
ing system from 0 (no clinical sign) to 100 (most severe 
signs) was designed. Intensity and extent of pharyngitis, 
gingivitis and glossitis were assessed and multiplied 
(Table 1).
Every week, haematological parameters were investi-
gated in order to detect adverse effects. A complete blood 
count was measured using an automatic analyser (Cell-
Dyn 3500 R; Abbott Diagnostics); haematocrit was eval-
uated manually using a micro-haematocrit centrifuge 
(Hettich). A serum biochemistry profile was performed 
every 3 weeks with an automatic analyser (Hitachi 717 
Autoanalyzer; Boehringer), a flame photometer (Effox 
5053; Eppendorf) and a chloride analyser (Corning 925; 
Corning). The CD4+ and CD8+ cell counts and the CD4/
CD8 ratio, as well as FeLV p27 antigen levels, were deter-
mined every 3 weeks.
CD4+ and CD8+ cell counts
To evaluate T-lymphocyte subsets, lymphocytes were 
stained for cell surface expression of CD3, CD4 and 
CD8 as described previously,14 and counted using a 
Table 1 Scoring of clinically evident stomatitis (0 = no clinical sign; 100 = most severe signs). The final score represents 
grades for intensity (from 0 = no clinical sign to 10 = most severe signs) and extent (from 0 = no clinical sign to 10 = 
most severe signs) of pharyngitis, gingivitis and glossitis. The product of the extent and intensity score for each of the 
three regions was summed and divided by three
Stomatitis (score 0 to 100)
Pharyngitis Intensity (0–10) × extent (0–10)
Gingivitis Intensity (0–10) × extent (0–10)
Glossitis Intensity (0–10) × extent (0–10)
Status of stomatitis (Stomatitis + gingivitis + glossitis)/3
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fluorescence-activated cell sorter (Becton Dickinson). In 
general, 30,000 cells were measured and analysed with 
two different software programs (Cell Quest version 
1.1.1 and Macintosh Quadra 650). The absolute CD4+ 
and CD8+ cell count was measured, and the CD4/CD8 
ratio was calculated.
FeLV-p27-Antigen ELISA
Quantitative determination of FeLV p27 antigen was 
performed as described previously using an ELISA for 
quantification of free serum p27 antigen in relation to a 
defined positive control.15
Statistical evaluation
Prior to the study, a power analysis was conducted to 
determine the number of cats needed in each group so as 
to detect significant differences among the treatment 
groups, and between the treatment groups and the pla-
cebo group. Using data from the pilot study by Zeidner 
et al,12 assuming a SD in antigen decrease (80%) of 400 
ng/ml, a power of 90% and α = 0.05, at least 10 cats per 
group were calculated to be necessary to detect an anti-
gen decrease of at least 60% in naturally-infected cats. 
This percentage decrease was chosen as it was consid-
ered likely to be clinically relevant. Thus, based on the 
power analysis, 10–12 cats per group were included in 
the study.
Stomatitis score, all laboratory parameters, lympho-
cyte subsets and FeLV p 27 antigen concentrations were 
all compared among treatment groups using commercial 
software (SPSS). Change over time was determined by 
calculating the difference between the mean values at 
the beginning and end of therapy. The Kruskall–Wallis 
test was used to analyse differences among groups. The 
Wilcoxon test was used to compare each drug group 




All cats were still alive at the end of the study. Stomatitis 
was the most frequently observed clinical sign (37/44 
cats; 81.8%) and was the only clinical variable statisti-
cally compared among groups. No significant difference 
in stomatitis score was detected among treatment groups 
(Table 2).
Likewise, no significant differences among groups 
were detected for any immunological parameters (ie, 
CD4+ and CD8+ counts, and CD4/CD8 ratio). However, 
in cats treated with both AZT and huIFN-α2a, median 
absolute CD4+ count increased by more than 100% (Table 
2), whereas no significant increase was seen in the pla-
cebo group.
No significant differences in the development of the 
FeLV p27 antigen concentrations were observed among 
the groups.
Adverse effects
No significant differences in haematological or biochem-
istry parameters were detected among treatment groups. 
Haematocrit and haemoglobin concentration of only one 
cat treated with AZT decreased to below the reference 
interval during the treatment period.
Discussion
Although treatment of cats infected experimentally with 
FeLV with huIFN-α in combination with AZT is effec-
tive,12,13 treatment of naturally-infected cats in the present 
study using the same drugs was not effective. This was 
despite application of the same huIFN-α concentration 
(105 IU/kg) used in one of the successful experimental 
studies.13 Zeidner et al13 prophylactically treated cats 
infected experimentally with FeLV using a combination 
of AZT and IFN-α2a, and could prevent the development 
of persistent viraemia.12 In another study evaluating the 
Table 2 Changes in variables during the treatment period. Numbers indicate the median difference between end and 
beginning of treatment, presented as % of the values at beginning of treatment
Parameter huIFN-α2a AZT huIFN-α2a/AZT Placebo P*
Stomatitis −4.8 0.6 −8.7 1.1 0.080
Haemoglobin (g/dl) −4.5 −9.9 −16.6 −5.7 0.265
Haematocrit (%) −1.0 −3.1 −4.9 −1.6 0.703
WBC count (cells/µl) 2.8 −5.2 −4.7 −4.0 0.893
Relative CD4 count (%) 3.8 2.6 4.1 −4.9 0.444
Relative CD8 count (%) −0.8 −1.6 2.4 2.2 0.443
Absolute CD4 count (cells/µl) −2.0 −12.3 106.2 5.6 0.335
Absolute CD8 count (cells/µl) −33.0 −22.5 96.7 63.7 0.089
CD4/CD8 ratio 23.1 66.7 −11.8 −18.2 0.192
FeLV p27 antigen 0.3 −3.6 −1.5 1.2 0.988
*Comparison between groups by Kruskall–Wallis test
WBC = white blood cell; FeLV = feline leukaemia virus; huIFN-α2a = human interferon-α2a
 at LMU Muenchen on March 11, 2015jfm.sagepub.comDownloaded from 
670 Journal of Feline Medicine and Surgery 15(8)
therapeutic effect of IFN-α2a and AZT used alone or in 
combination to treat experimentally-infected FeLV pre-
symptomatic cats with established FeLV infection and 
persistent antigenaemia, Zeidner et al13 showed that 
treatment resulted in a significant decrease in circulating 
FeLV p27 antigen. On the contrary, in the present study, 
neither AZT nor IFN-α2a, nor the combination of the 
compounds, resulted in a significant decrease in FeLV 
p27 antigenaemia.
When given alone in other studies, AZT was also not 
very effective in experimentally- or naturally-infected 
cats.11,13,16 Only when given prophylactically (before 
experimental infection), AZT had some effect and could 
prevent development of persistent viraemia.16,17 
Although it was not to be expected that AZT alone 
would have a notable effect in naturally-infected FeLV 
cats, the combination of AZT and IFN-α2a was consid-
ered a promising approach.12 However, combination 
treatment in the present study was not associated with a 
statistically significant decrease in FeLV p27 antigen or 
improvement of clinical, laboratory or immunological 
variables. There are several possible reasons for these 
different results among studies. First, the difference 
between experimental and natural infection might be 
important. It is possible that experimentally-infected 
cats received treatment at an earlier stage of infection 
than did naturally-infected cats. In the early phase of 
infection, FeLV is potentially more vulnerable to antivi-
ral drug effects than it is in cats that are already infected 
for a longer time, which is likely the case in naturally-
infected cats. During early viraemia, many cats are able 
to overcome viraemia and become FeLV antigen nega-
tive.4 Zeidner et al13 started treatment 3 weeks after 
infection, at a time point when, in many cats, a spontane-
ous decrease in p27 antigen is possible, even without 
treatment. However, once FeLV infection is established, 
as was likely in naturally-infected cats assessed in the 
present study, it might be much more difficult to influ-
ence viraemia and antigen concentration. Furthermore, 
in the studies of Zeidner et al,12,13 the cats were infected 
with one specific FeLV isolate (FeLV-FAIDS 61E/C)13 
that might have been more susceptible to treatment, 
whereas cats in the present study were infected naturally 
with unknown, but likely different, FeLV strains. 
Another explanation might be the different dosage of 
AZT used in the present study (5 mg/kg) compared 
with the regimen of Zeidner et al (20 mg/kg).13 This 
lower dosage was chosen in order to lower the risk of 
development of anaemia. Severe anaemia develops dur-
ing treatment of cats infected naturally with FeLV at 
AZT dosages of 10 mg/kg.11 Thus, a rather cautious 
approach was chosen in the present study. The huIFN-
α2a dosage of 105 IU/kg q24h used in the present study 
equates to the middle dosage used in one of the studies 
by Zeidner et al13 and was chosen in the present study 
because a higher dosage in cats would be expected 
to stimulate development of neutralising antibodies 
against the heterologous interferon within 3 weeks.
None of the drugs used in the present study had a 
significant effect on the most frequently observed clini-
cal sign of stomatitis. This is in contrast to several pla-
cebo-controlled trials, in which treatment with AZT 
improved stomatitis in naturally-infected FIV cats.18–20 It 
is possible that AZT is not as effective against FeLV as it 
is against FIV because AZT is a drug designed for use in 
humans infected with HIV, and HIV and FIV reverse 
transcriptases are more similar to each other than are the 
enzymes of HIV and FeLV.21
Also, no significant effect of treatment was observed 
on CD4+ counts, CD8+ counts or the CD4/CD8 ratio in 
any group. These values might not be such valuable 
parameters for assessing immune function in cats infected 
with FeLV because, in contrast to FIV-infected cats, CD4+ 
cells are not selectively destroyed in FeLV-infected cats.11
Surprisingly, in the present study administration of 
AZT of huIFN-α2a alone or in combination was not asso-
ciated with any adverse effects in most of the cats. By con-
trast, Zeidner et al12,13 observed adverse effects, such as 
anorexia and weight loss, in cats receiving huIFN-α2a. In 
another study, tissue irritation and necrosis were described 
after subcutaneous injection of huIFN-α2a.22 In addition, 
AZT can lead to anaemia and neutropenia due to a bone 
marrow depression.13,19,23,24 In the present study, a slight 
decrease in haematocrit and haemoglobin concentration 
was noted in all study groups, including the placebo 
group — a fact that could be explained by the frequent 
(once-weekly) blood collection throughout the course of 
the study. However, the amount of blood required for the 
laboratory tests reported in the article should not push 
most cats into anaemia, especially with the generous 
splenic reserves of erythrocytes in cats. Despite this gen-
eral trend, only one cat (receiving AZT alone) developed 
haematocrit values and haemoglobin concentration below 
the reference interval. Thus, AZT may be associated with 
anaemia, but only in individual cats.
One limitation of the present study was the rather 
short treatment period (6 weeks). It is possible that 
changes in some variables would have been more pro-
nounced and a significant effect might have been observed 
if treatment was continued for a longer period. However, 
this was not possible because IFN-α2a-treated animals 
tend to develop neutralising antibodies to IFN-α2a within 
about 7 weeks of treatment depending on the dose admin-
istered.13 Another limitation of the present study was that 
the duration of FeLV infection prior to therapy was not 
known. This likely resulted in a heterogeneous study pop-
ulation with respect to infection status.
Although group size in the present study was deter-
mined using power analysis prior to the study, this 
required estimation of a number of poorly understood 
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variables, and it is possible that the failure to detect sig-
nificant differences among the study groups might have 
resulted from insufficient cat numbers studied rather 
than to an actual lack of effect. Finally, provirus load was 
not quantified in the present study. It is possible that pro-
virus load may have differed among treatment groups; 
however, changes in provirus load are typically seen in 
feline patients on extended treatment regimens, whereas 
antigen detection is considered a valuable tool to deter-
mine viral replication rate and therefore better for detect-
ing earlier differences.
Conclusions
It can be concluded from the present study that although 
efficacy of ‘high-dose’ huIFN-α2a and AZT has been 
demonstrated in cats infected experimentally with FeLV, 
no significant effect of these compounds (as adminis-
tered here) could be demonstrated in cats naturally 
infected with FeLV. However, it should also be noted 
that no adverse effects were seen. It is possible that effi-
cacy could be observed if these drugs were administered 
at a very early stage of FeLV infection.
Acknowledgements The authors thank the Clinic of Small 
Animal Medicine of the LMU University of Munich for pro-
viding financial support of the study and Professor Dr David 
Maggs for carefully reviewing the manuscript.
Funding This research received no grant from any funding 
agency in the public, commercial, or not-for-profit sectors.
Conflict of interest The authors do not have any potential 
conflicts of interest to declare.
References
 1 Jarrett WF, Crawford EM, Martin WB and Davie F. A Virus-
like particle associated with leukemia (lymphosarcoma). 
Nature 1964; 202: 567–569.
 2 Hoover EA and Mullins JI. Feline leukemia virus infection 
and diseases. J Am Vet Med Assoc 1991; 199: 1287–1297.
 3 Leutenegger CM, Hofmann-Lehmann R, Riols C, et al. 
Viral infections in free-living populations of the Euro-
pean wildcat. J Wildl Dis 1999; 35: 678–686.
 4 Levy J, Crawford C, Hartmann K, et al. 2008 American 
Association of Feline Practitioners’ feline retrovirus man-
agement guidelines. J Feline Med Surg 2008; 10: 300–316.
 5 Jameson P and Essex M. Inhibition of feline leukemia 
virus replication by human leukocyte interferon. Antiviral 
Res 1983; 3: 115–120.
 6 Cummins JM, Tompkins MB, Olsen RG, et al. Oral use of 
human alpha interferon in cats. J Biol Response Mod 1988; 7: 
513–523.
 7 Weiss RC, Cummins JM and Richards AB. Low-dose orally 
administered alpha interferon treatment for feline leuke-
mia virus infection. J Am Vet Med Assoc 1991; 199: 1477–1481.
 8 Fischl MA, Richman DD, Grieco MH, et al. The efficacy of 
azidothymidine (AZT) in the treatment of patients with 
AIDS and AIDS-related complex. A double-blind, pla-
cebo-controlled trial. New Engl J Med 1987; 317: 185–191.
 9 Tateyama S, Priosoeryanto BP, Yamaguchi R, et al. In vitro 
growth inhibition activities of recombinant feline inter-
feron on all lines derived from canine tumours. Res Vet Sci 
1995; 59: 275–277.
 10 Nelson P, Sellon R, Novotney C, et al. Therapeutic effects 
of diethylcarbamazine and 3’-azido-3’-deoxythymidine 
on feline leukemia virus lymphoma formation. Vet Immu-
nol Immunopathol 1995; 46: 181–194.
 11 Hartmann K, Donath A, Beer B, et al. Use of two virustatica 
(AZT, PMEA) in the treatment of FIV and of FeLV sero-
positive cats with clinical symptoms. Vet Immunol Immu-
nopathol 1992; 35: 167–175.
 12 Zeidner NS, Rose LM, Mathiason-DuBard CK, et al. Zid-
ovudine in combination with alpha interferon and 
interleukin-2 as prophylactic therapy for FeLV-induced 
immunodeficiency syndrome (FeLV-FAIDS). J Acquir 
Immune Defic Syndr 1990; 3: 787–796.
 13 Zeidner NS, Myles MH, Mathiason-DuBard CK, et al. 
Alpha interferon (2b) in combination with zidovudine for 
the treatment of presymptomatic feline leukemia virus-
induced immunodeficiency syndrome. Antimicrob Agents 
Chemother 1990; 34: 1749–1756.
 14 Hoffmann-Fezer G, Thum I, Herbold M, et al. T-helper and 
T-suppressor lymphocyte subpopulations in the periph-
eral blood of spontaneously FIV-positive cats. Tierarztliche 
Praxis 1991; 19: 682–686 [in German].
 15 Lutz H, Pedersen NC and Theilen GH. Course of feline 
leukemia virus infection and its detection by enzyme-
linked immunosorbent assay and monoclonal antibodies. 
Am J Vet Res 1983; 44: 2054–2059.
 16 Tavares L, Roneker C, Johnston K, et al. 3’-Azido-3’-de-
oxythymidine in feline leukemia virus-infected cats: a 
model for therapy and prophylaxis of AIDS. Cancer Res 
1987; 47: 3190–3194.
 17 Mathes LE, Polas PJ, Hayes KA, et al. Pre- and postexpo-
sure chemoprophylaxis: evidence that 3’-azido-3’-dide-
oxythymidine inhibits feline leukemia virus disease by 
a drug-induced vaccine response. Antimicrob Agents Che-
mother 1992; 36: 2715–2721.
 18 Hartmann K. AZT in the treatment of feline immunodefi-
ciency virus infection: part 1. Feline Pract 1995; 23: 16–21.
 19 Hartmann K. AZT in the treatment of feline immunodefi-
ciency virus infection: part 2. Feline Pract 1995; 23: 13–20.
 20 Hartmann K. Feline immunodeficiency virus infection. 
Brit Vet J 1998; 155: 123–137.
 21 North T, North G and Pedersen N. Feline immunodefi-
ciency virus, a model for reverse transcriptase-targeted 
chemotherapy for acquired immune deficiency syn-
drome. Antimicrob Agents Chemother 1989; 33: 915–919.
 22 Zimmermann C, Walther EU, Goebels N, et al. Interferon 
beta-1b for treatment of secondary chronic progressive 
multiple sclerosis. Der Nervenarzt 1999; 70: 759–763 [in Ger-
man].
 23 McLeod GX and Hammer SM. Zidovudine: five years 
later. Ann Intern Med 1992; 117: 487–501.
 24 Haschek WM, Weigel RM, Scherba G, et al. Zidovudine 
toxicity to cats infected with feline leukemia virus. Fun-
dam Appl Toxicol 1990; 14: 764–775.
 at LMU Muenchen on March 11, 2015jfm.sagepub.comDownloaded from 
